MD
Pediatrix Medical Group, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S May 13 1 insider sell $855.7K at $23.75
- A Aug 19 Jefferies downgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $855.7K.
- InstitutionsBULLISH
Q2 2026: 29 added (0 new), 9 trimmed or exited.
- AnalystsBULLISH
8 of 15 rate it Buy or better. Price is above every target.
- TrendUPTREND
9% above its 50-day average. New closing high $29.55 on Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | TRIM | $55.5M |
| FULLER & THALER ASSET MANAGEMENT, INC. | ADD | $43.6M |
| Allspring Global Investments Holdings, LLC | ADD | $42.3M |
| Rockefeller Capital Management L.P. | ADD | $33.9M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | DOUBLED | $25.0M |
| ROYCE & ASSOCIATES LP | ADD | $23.2M |
| FMR LLC | TRIM | $18.8M |
| Tidal Investments LLC | DOUBLED | $15.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is above the highest target. Median implies −4%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 19, 2026 | Jefferies DOWNGRADE | Hold |
| Aug 6, 2026 | UBS MAINTAIN | Neutral |
| Jul 14, 2026 | Truist Securities MAINTAIN | Hold |
| May 12, 2026 | UBS MAINTAIN | Neutral |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 10, 2026 | Linynsky Laura A Director | TO ISSUER | $160.9K |
| Aug 14, 2026 | Young Sylvia Jean Director | TO ISSUER | $492.5K |
| Aug 12, 2026 | McEachin Thomas Director | AWARD | $12.5K |
| Aug 12, 2026 | Young Sylvia Jean Director | AWARD | $12.5K |
| Aug 12, 2026 | SANSONE GUY P Director | AWARD | $12.5K |
| Aug 12, 2026 | Newman Kurt Douglas Director | AWARD | $12.5K |
| Aug 12, 2026 | Rucker Michael A. Director | AWARD | $12.5K |
| Aug 12, 2026 | Linynsky Laura A Director | AWARD | $12.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 0 bullish · 0 bearish · 5 neutral- NEUTRAL 8-KAug 4, 2026
Pediatrix Medical Group reported Q2 2026 Adjusted EPS of $0.63, beating the $0.59 consensus by…
The modest beat on both revenue and EPS is positive but largely anticipated after the July 15 pre-announcement. The reaffirmed guidance and stable payor mix remove downside risk, but volume declines…
- NEUTRAL 8-KJul 24, 2026
Pediatrix Medical Group filed an 8-K announcing the departure of EVP, General Counsel, Chief…
This is a routine executive succession with no immediate trading signal. Monitor for any future strategic shifts under the new General Counsel, but no near-term price catalyst is expected.
- NEUTRAL 8-KJul 15, 2026
Pediatrix Medical Group issued a Q2 2026 business update confirming stable payor mix and no…
The update contains no material new information; the stock is unlikely to react significantly. Focus on the Q2 earnings release on August 4, 2026 for actual financial results and any guidance changes.
- NEUTRAL DEFA14AApr 17, 2026
Pediatrix Medical Group is holding its 2026 Annual Meeting of Shareholders on May 7, 2026, to vote…
Investors should consider the board's strong support for John M. Starcher, Jr. despite the ISS and Glass Lewis recommendation against his re-election. The primary consideration is whether Starcher's…
All MD filing & press-release reports (5)
- 8-K reportAug 4, 2026
- 8-K reportJul 24, 2026
- 8-K reportJul 15, 2026
- DEFA14A reportApr 17, 2026
- DEFA14A reportMar 27, 2026